Provided by Tiger Fintech (Singapore) Pte. Ltd.

Arcutis Biotherapeutics Inc.

14.37
+0.86006.37%
Pre-market: 14.640.2700+1.88%04:58 EDT
Volume:2.44M
Turnover:34.68M
Market Cap:1.71B
PE:-13.81
High:14.55
Open:13.90
Low:13.67
Close:13.51
Loading ...

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
07 Jun

Press Release: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dow Jones
·
07 Jun

Patrick J. Heron, Director, Reports Acquisition of Arcutis Biotherapeutics Inc. Common Shares

Reuters
·
06 Jun

Arcutis Biotherapeutics (ARQT) Gets a Buy from Guggenheim

TIPRANKS
·
02 Jun

Masaru Matsuda, Officer, Reports Disposal of Arcutis Biotherapeutics Inc. Common Shares

Reuters
·
30 May

Director Patrick J. Heron Reports Acquisition of Common Shares of Arcutis Biotherapeutics Inc

Reuters
·
24 May

Arcutis Biotherapeutics (ARQT) Gets a Buy from TD Cowen

TIPRANKS
·
23 May

Arcutis Biotherapeutics Price Target Maintained With a $20.00/Share by Needham

Dow Jones
·
23 May

Arcutis Biotherapeutics: Buy Rating Affirmed on Strong FDA Approvals and Promising Pipeline

TIPRANKS
·
23 May

Arcutis Biotherapeutics' Foam Psoriasis Treatment Gets FDA Approval

MT Newswires Live
·
23 May

Arcutis Biotherapeutics reports FDA approves sNDA for Zoryve topical foam

TIPRANKS
·
23 May

Arcutis Biotherapeutics Shares Add to Gains With Volume Pickup After FDA Approval for Topical Foam Plaque Psoriasis Treatment, Last up 1.3% at $13.95

THOMSON REUTERS
·
23 May

FDA Approves Arcutis Biotherapeutics' ZORYVE® Topical Foam for Plaque Psoriasis Treatment in Adults and Adolescents

Reuters
·
23 May

Arcutis’ Zoryve® (Roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older

THOMSON REUTERS
·
23 May

Top Executive Sells Thousands of Arcutis Biotherapeutics Shares!

TIPRANKS
·
21 May

Officer Larry Todd Edwards Reports Disposal of Common Shares in Arcutis Biotherapeutics Inc

Reuters
·
21 May

Director Patrick J. Heron Reports Acquisition of Arcutis Biotherapeutics Inc. Common Shares

Reuters
·
20 May

Director Patrick J. Heron Reports Acquisition of Common Shares in Arcutis Biotherapeutics Inc

Reuters
·
16 May

Arcutis announces publication of Genital Psoriasis Wellness Consortium statement

TIPRANKS
·
15 May

Buy Rating for Arcutis Biotherapeutics: Long-term Growth Potential and Upcoming Catalysts

TIPRANKS
·
12 May